AAPL   324.63 (-0.15%)
MSFT   185.43 (+0.04%)
FB   231.12 (+0.42%)
GOOGL   1,439.58 (+0.02%)
AMZN   2,502.54 (+0.97%)
NVDA   351.95 (+0.33%)
CGC   16.43 (-0.85%)
MU   49.29 (+0.76%)
ACB   14.11 (-1.33%)
F   6.26 (+1.13%)
DIS   122.66 (+0.39%)
BAC   25.89 (-0.38%)
BA   180.75 (+4.38%)
AAPL   324.63 (-0.15%)
MSFT   185.43 (+0.04%)
FB   231.12 (+0.42%)
GOOGL   1,439.58 (+0.02%)
AMZN   2,502.54 (+0.97%)
NVDA   351.95 (+0.33%)
CGC   16.43 (-0.85%)
MU   49.29 (+0.76%)
ACB   14.11 (-1.33%)
F   6.26 (+1.13%)
DIS   122.66 (+0.39%)
BAC   25.89 (-0.38%)
BA   180.75 (+4.38%)
AAPL   324.63 (-0.15%)
MSFT   185.43 (+0.04%)
FB   231.12 (+0.42%)
GOOGL   1,439.58 (+0.02%)
AMZN   2,502.54 (+0.97%)
NVDA   351.95 (+0.33%)
CGC   16.43 (-0.85%)
MU   49.29 (+0.76%)
ACB   14.11 (-1.33%)
F   6.26 (+1.13%)
DIS   122.66 (+0.39%)
BAC   25.89 (-0.38%)
BA   180.75 (+4.38%)
AAPL   324.63 (-0.15%)
MSFT   185.43 (+0.04%)
FB   231.12 (+0.42%)
GOOGL   1,439.58 (+0.02%)
AMZN   2,502.54 (+0.97%)
NVDA   351.95 (+0.33%)
CGC   16.43 (-0.85%)
MU   49.29 (+0.76%)
ACB   14.11 (-1.33%)
F   6.26 (+1.13%)
DIS   122.66 (+0.39%)
BAC   25.89 (-0.38%)
BA   180.75 (+4.38%)
Log in

NYSE:RCUSArcus Biosciences Stock Price, Forecast & News

$30.44
-0.75 (-2.40 %)
(As of 06/4/2020 10:07 AM ET)
Add
Compare
Today's Range
$29.75
Now: $30.45
$31.14
50-Day Range
$15.58
MA: $29.80
$36.56
52-Week Range
$6.30
Now: $30.45
$37.41
Volume63,111 shs
Average Volume1.03 million shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.31
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Read More
Arcus Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone510-694-6200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15 million
Book Value$3.57 per share

Profitability

Net Income$-84,710,000.00
Net Margins-631.95%

Miscellaneous

Employees108
Market Cap$1.40 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive RCUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.

Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions

How has Arcus Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RCUS stock has increased by 83.9% and is now trading at $31.20. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Arcus Biosciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arcus Biosciences.

When is Arcus Biosciences' next earnings date?

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Arcus Biosciences.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences Inc (NYSE:RCUS) released its earnings results on Tuesday, May, 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.07. The company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $2 million. Arcus Biosciences had a negative net margin of 631.95% and a negative return on equity of 55.90%. View Arcus Biosciences' earnings history.

What price target have analysts set for RCUS?

7 brokers have issued 1-year price targets for Arcus Biosciences' stock. Their forecasts range from $21.00 to $48.00. On average, they expect Arcus Biosciences' share price to reach $35.38 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price. View analysts' price targets for Arcus Biosciences.

Has Arcus Biosciences been receiving favorable news coverage?

News articles about RCUS stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arcus Biosciences earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the stock's share price in the immediate future. View the latest news aboutArcus Biosciences.

Are investors shorting Arcus Biosciences?

Arcus Biosciences saw a decrease in short interest in May. As of May 15th, there was short interest totaling 331,600 shares, a decrease of 50.7% from the April 30th total of 672,900 shares. Based on an average daily trading volume, of 562,500 shares, the short-interest ratio is currently 0.6 days. Approximately 1.2% of the shares of the stock are sold short. View Arcus Biosciences' Current Options Chain.

Who are some of Arcus Biosciences' key competitors?

What other stocks do shareholders of Arcus Biosciences own?

Who are Arcus Biosciences' key executives?

Arcus Biosciences' management team includes the following people:
  • Dr. Terry Rosen Ph.D., Co-Founder, Chairman & CEO (Age 59)
  • Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 61)
  • Mr. Steven Chan, Consultant (Age 47)
  • Ms. Rekha Hemrajani, Chief Operating & Financial Officer (Age 49)
  • Dr. Stephen Young Ph.D., VP of Technology (Age 50)

When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.05%), State Street Corp (1.40%), Franklin Resources Inc. (0.99%), Geode Capital Management LLC (0.96%), JPMorgan Chase & Co. (0.84%) and Invesco Ltd. (0.62%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View institutional ownership trends for Arcus Biosciences.

Which institutional investors are selling Arcus Biosciences stock?

RCUS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Two Sigma Investments LP, Morgan Stanley, GSA Capital Partners LLP, UBS Group AG, Deutsche Bank AG, and MML Investors Services LLC. View insider buying and selling activity for Arcus Biosciences.

Which institutional investors are buying Arcus Biosciences stock?

RCUS stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Invesco Ltd., Balyasny Asset Management LLC, Federated Hermes Inc., Nuveen Asset Management LLC, Geode Capital Management LLC, DAFNA Capital Management LLC, and Trexquant Investment LP. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg, and Terry J Rosen. View insider buying and selling activity for Arcus Biosciences.

How do I buy shares of Arcus Biosciences?

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $31.20.

How big of a company is Arcus Biosciences?

Arcus Biosciences has a market capitalization of $1.44 billion and generates $15 million in revenue each year. The company earns $-84,710,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.

What is Arcus Biosciences' official website?

The official website for Arcus Biosciences is www.arcusbio.com.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.